Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy
| Autor: | S S Marwah, R T Hughes, D. Bareford, Paul Harrison |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male medicine.medical_specialty Neutropenia Time Factors Adolescent Iron medicine.medical_treatment Bleomycin Gastroenterology Pathology and Forensic Medicine chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine chemistry.chemical_classification Chemotherapy medicine.diagnostic_test business.industry Lymphoma Non-Hodgkin Transferrin General Medicine Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Lymphoma Leukemia chemistry Leukemia Myeloid Acute Disease Immunology Toxicity Serum iron Female business Protein Binding Research Article |
| Zdroj: | Journal of Clinical Pathology. 47:350-352 |
| ISSN: | 0021-9746 |
| DOI: | 10.1136/jcp.47.4.350 |
| Popis: | AIMS--To investigate and characterise the appearance of non-transferrin bound iron (NTBI) in the serum of patients after cytotoxic chemotherapy and to compare this with the onset and duration of neutropenia. METHOD--Non-transferrin bound iron was measured by a bleomycin assay in patients undergoing intensive chemotherapy for treatment of acute leukaemia or lymphoma. RESULTS--NTBI was detected after 26 of 27 courses of chemotherapy and lasted for a mean of 14.5 days. The presence of NTBI correlated with the serum iron binding saturation, but not with serum ferritin. Neutropenia occurred after all courses of chemotherapy and lasted for a mean of 20.0 days. NTBI and neutropenia occurred concurrently after 23 courses of chemotherapy, and had a mean joint duration of 9.5 days. CONCLUSIONS--NTBI is consistently present in the serum of patients after cytotoxic chemotherapy, often at the same time as the patient is neutropenic. This may be an additional risk factor for the development of infective episodes after chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|